



September 14, 2020

Santen, Verily Announce Joint Venture

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka City, hereafter Santen) announced today, that Santen and Verily Life Sciences LLC (Headquartered in San Francisco, USA, hereinafter Verily), a subsidiary of Alphabet and is engaged in the life sciences business, have established a joint venture company which they have been preparing since February of this year.

The new joint venture is driven by a mission to improve eye health for people everywhere, starting by developing solutions to support modern ophthalmology practice globally. Combining Santen's industry knowledge and technology in ophthalmology and Verily's expertise in development of connected, integrated medical devices and machine learning, the new company will create and commercialize unique ophthalmic devices and comprehensive tech-enabled solutions.

The outline of the joint venture is as follows.

Company: Twenty Twenty Therapeutics

Establishment: August 14, 2020

Representative's name: Dimitri Azar, CEO

Address: 259 E Grand Avenue, EGA 3 -3 rd floor, South San Francisco, CA, 94080

References:

Press Release: Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Devices (February 4, 2020)

<https://ssl4.eir-parts.net/doc/4536/tdnet/1790368/00.pdf>

Contact

Akiko Yoshikawa

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: communication@santen.com Tel: +81-6-4802-9360,